Melphalan and Hypernatraemia - a phase IV clinical study of FDA data

Summary:

Hypernatraemia is reported as a side effect among people who take Melphalan (melphalan), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Neupogen, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Hypernatraemia when taking Melphalan. It is created by eHealthMe based on reports of 20,050 people who have side effects when taking Melphalan from the FDA, and is updated regularly.

What is Melphalan?

Melphalan has active ingredients of melphalan. eHealthMe is studying from 20,052 Melphalan users. Check the latest studies of Melphalan.

What is Hypernatraemia?

Hypernatraemia (an abnormally high plasma concentration of sodium ions) is found to be associated with 645 drugs and 807 conditions by eHealthMe. Check the latest studies of Hypernatraemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

20,050 people reported to have side effects when taking Melphalan.
Among them, 17 people (0.08%) have Hypernatraemia.

Among these 17 people:

How long have people been on Melphalan when they have Hypernatraemia? *

What is the gender of people who have Hypernatraemia when taking Melphalan? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Hypernatraemia when taking Melphalan? *

What are other drugs people take besides Melphalan? *

What are other side effects people have besides Hypernatraemia? *

Hypokalemia (low potassium): 8 people, 47.06%
Diarrhea: 8 people, 47.06%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 6 people, 35.29%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 35.29%
Mucosal Inflammation (infection of mucous membrane): 6 people, 35.29%
Infection: 6 people, 35.29%
Urinary Tract Infection: 5 people, 29.41%
Anaemia (lack of blood): 5 people, 29.41%
Thrombocytopenia (decrease of platelets in blood): 5 people, 29.41%
Fever: 5 people, 29.41%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 8 people, 47.06%
Pain: 3 people, 17.65%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 11.76%
Haematopoietic Stem Cell Mobilisation: 2 people, 11.76%
Respiratory Distress (difficulty in breathing): 1 person, 5.88%
Nausea And Vomiting: 1 person, 5.88%
Nausea (feeling of having an urge to vomit): 1 person, 5.88%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 1 person, 5.88%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 5.88%
Insomnia (sleeplessness): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan and have Hypernatraemia?

- Check whether Hypernatraemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Melphalan:

Melphalan (20,052 reports)

Hypernatraemia treatments and more:

Hypernatraemia (6,339 reports)

Browse all side effects of Melphalan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypernatraemia:

Hypernatraemia (645 drugs)

Browse all the conditions that are associated with Hypernatraemia:

Hypernatraemia (807 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on melphalan (the active ingredients of Melphalan) and Melphalan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.